A comprehensive 2026 guide to UK online casinos with a 400% bonus. Understand wagering, find the best offers, and see if a 4x match is actually worth it. Read our full guide to 400% casino bonuses
Micot Pharma’s MT200605 Achieves Primary Endpoint in Phase II Trial, Novel Integrated Multi-stage Neuroprotection Mechanism to Be Presented at WSC 2026
HONG KONG, August 7, 2026 – (ACN Newswire) – On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot Pharma”; 2335.HK) announced positive topline data from the Phase II…
Healthcare Demand Upgrade, EPS Creative Health Technology Group (3860.HK) Expands Its Healthcare Business
HONG KONG, July 24, 2026 – (JCN Newswire) – As Asia’s demographic structure evolves and health awareness continues to rise, the healthcare market is undergoing sustained upgrading. Demand across high-end…
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Avantor India Appointed as Exclusive Distributor for Sartorius Filter Papers to Serve India’s Laboratory Consumables Sector
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries,announced today it has been appointed the exclusive distributor of Sartorius Filter Papers…
Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use…
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, further enhancing patient access to the medication
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National…
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the Product), a Class 1 therapeutic biological…
Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of DMX-200 in Greater China (Chinese mainland,…
Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio
Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known…
Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin’s Potential Across Metabolic Disease
Hua Medicine (“the Company”, stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator…
ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of…
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the Company has obtained exclusive rights for…
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence
Everest Medicines (HKG: 1952) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary…
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the…
Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK
SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief…
International Healthcare Week opens today, fuelling healthcare breakthroughs
ASGH and Medical Fair open concurrently, showcasing cutting-edge AI, Robotics and MedTech The fifth International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), opens today, featuring…
Holista Executes Binding JV for Collie Collagen Facility
Holista Colltech Limited (ASX: HCT) (Holista or the Company) is pleased to announce that it has entered into a binding Joint Venture Agreement with Swang Chai Chuan Limited (HKEX: 2321)…
Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX
HONG KONG, Apr 28, 2026 – (ACN Newswire) – Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical…
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the Agreement)…